APA (7th ed.) Citation

Wang, Q., Tu, M., Lu, N., Xu, D., Wu, Y., & Jiang, K. (2025). 929P The efficacy and safety of surufatinib combined with chemotherapy in the first-line treatment of advanced periampullary carcinoma: A single arm, prospective, exploratory clinical study. Annals of Oncology, 36, S608. https://doi.org/10.1016/j.annonc.2025.08.1498

Chicago Style (17th ed.) Citation

Wang, Q., M. Tu, N. Lu, D. Xu, Y. Wu, and K. Jiang. "929P The Efficacy and Safety of Surufatinib Combined with Chemotherapy in the First-line Treatment of Advanced Periampullary Carcinoma: A Single Arm, Prospective, Exploratory Clinical Study." Annals of Oncology 36 (2025): S608. https://doi.org/10.1016/j.annonc.2025.08.1498.

MLA (9th ed.) Citation

Wang, Q., et al. "929P The Efficacy and Safety of Surufatinib Combined with Chemotherapy in the First-line Treatment of Advanced Periampullary Carcinoma: A Single Arm, Prospective, Exploratory Clinical Study." Annals of Oncology, vol. 36, 2025, p. S608, https://doi.org/10.1016/j.annonc.2025.08.1498.